Clear Cell Ovarian Cancer Patients Lacking ARID1A Protein Could Benefit from ENMD-2076 Treatment, Study Reports
News
Results from a Phase 2 clinical trial indicate that an investigational drug by CASI Pharmaceuticals, known as ENMD-2076, may be beneficial for patients with rare clear cell ovarian cancer (CCOC), particularly ... Read more